Marielle Fournel

Molecular Biology Consortium — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index2.4kcitations49works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Histone Deacetylase Inhibitors Research(24), Protein Degradation and Inhibitors(20), Epigenetics and DNA Methylation(6), Peptidase Inhibition and Analysis(6), Cancer, Hypoxia, and Metabolism(5)

Publications49 total

Data from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors
Bioorganic & Medicinal Chemistry Letters·2015· 29 citedOpen Access
Abstract 930: Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies.
Cancer Research·2013· 5 cited
312 A Novel Assay for the Met Inhibitory Activity of MGCD265 in Plasma From Solid Tumor Patients in a Dose Escalating Phase I Study
European Journal of Cancer·2012· 4 cited
Clinical Effects of MGCD265, an oral Tyrosine Kinase Inhibitor, in Combination with Erlotinib or Docetaxel for Treatment of Advanced Gastroesophageal and Nsclc Tumors
Annals of Oncology·2012
A Phase I, Dose-Escalation Study of Mgcd265, A Multi-Targeted Oral Tyrosine Kinase Receptor Inhibitor, for Treatment of Advanced Solid Tumors
Annals of Oncology·2012
MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel.
Journal of Clinical Oncology·2012· 4 cited
MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.
Journal of Clinical Oncology·2012· 2 cited
Abstract 1790: The combination of MGCD265, a Met/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis
Cancer Research·2012· 13 cited
MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase I clinical experience.
Journal of Clinical Oncology·2011· 6 cited
Abstract 3610: Potent preclinical anti-tumor activity of MGCD265, an oral Met/VEGFR multitargeted kinase inhibitor in clinical development, in combination with taxanes
Cancer Research·2011
Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.
Journal of Clinical Oncology·2010· 18 cited
Abstract 3612: Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor
Cancer Research·2010· 3 cited
Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors
Bioorganic & Medicinal Chemistry Letters·2009· 21 citedOpen Access
SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103)
Bioorganic & Medicinal Chemistry Letters·2008· 7 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Jeffrey M. Besterman(37), Zuomei Li(24), Marie-Claude Trachy-Bourget(20), Oscar Moradei(19), Jubrail Rahil(18), Claire Bonfils(17), Pu Yan(16), Aihua Lu(16), Ann Kalita(15), Jinru Wang(14), Silvana Leit(14), Sylvain Lefèbvre(13), Daniel Delorme(13), A. Robert MacLeod(12), Sylvie Fréchette(12), Arkadii Vaisburg(12), Christiane R. Maroun(12), Jianhong Liu(11), Marie‐France Robert(11), Hélène Ste-Croix(11)